about
Proteinuria in Patients with Solid Tumors Treated with Ramucirumab: A Systematic Review and Meta-AnalysisCritical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancersRisk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib: a meta-analysis.Doublet BRAF/MEK inhibition versus single-agent BRAF inhibition in the management of BRAF-mutant advanced melanoma, biological rationale and meta-analysis of published data.Risk of hematological toxicities in patients with solid tumors treated with ramucirumab: a meta-analysis.Risk of oral and gastrointestinal mucosal injury in patients with solid tumors treated with ramucirumab: a systematic review and meta-analysis.Risk of cardiovascular adverse events in patients with solid tumors treated with ramucirumab: A meta analysis and summary of other VEGF targeted agents.Adjuvant systemic treatment for elderly breast cancer patients; addressing safety concerns.Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.Risk of selected gastrointestinal toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.S-1-based regimens and the risk of oral and gastrointestinal mucosal injury: a meta-analysis with comparison to other fluoropyrimidines.Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis.Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis.S-1-based regimens for locally advanced/metastatic non-small-cell lung cancer: a meta-analysis.Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis.Risk of Distinctive Hair Changes Associated With Pazopanib in Patients With Renal Cell Carcinoma (RCC) Versus Patients Without RCC: A Comparative Systematic Review and Meta-analysis.Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib: a meta-analysis.A Multi-Institutional Comparison of Dynamic Contrast-Enhanced Magnetic Resonance Imaging Parameter Calculations.Treatment at a high-volume centre is associated with improved survival among patients with non-metastatic hepatocellular carcinoma.Deep Learning Algorithm for Auto-Delineation of High-Risk Oropharyngeal Clinical Target Volumes With Built-In Dice Similarity Coefficient Parameter Optimization Function.Exploring Applications of Radiomics in Magnetic Resonance Imaging of Head and Neck Cancer: A Systematic Review.Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysisGemcitabine-based chemotherapy for advanced biliary tract carcinomasUtilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United StatesAuto-delineation of oropharyngeal clinical target volumes using 3D convolutional neural networksMachine Learning Applications in Head and Neck Radiation Oncology: Lessons From Open-Source Radiomics ChallengesOutcomes of patients in the national cancer database treated non-surgically for localized rectal cancerAuthor Correction: Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapyEvaluating the Effect of Right-Censored End Point Transformation for Radiomic Feature Selection of Data From Patients With Oropharyngeal CancerA PET Radiomics Model to Predict Refractory Mediastinal Hodgkin LymphomaAn quality assurance study of contouring target volumes in thoracic tumors within a cooperative group settingPractical guidelines for handling head and neck computed tomography artifacts for quantitative image analysisS-1-based regimens and the risk of leucopenic complications; a Meta-analysis with comparison to other fluoropyrimidines and non fluoropyrimidinesData from a terminated study on iron oxide nanoparticle magnetic resonance imaging for head and neck tumorsClustering of Largely Right-Censored Oropharyngeal Head and Neck Cancer Patients for Discriminative Groupings to Improve Outcome PredictionRadiomics features of the primary tumor fail to improve prediction of overall survival in large cohorts of CT- and PET-imaged head and neck cancer patientsPrivacy-preserving distributed learning of radiomics to predict overall survival and HPV status in head and neck cancerRadiographic retropharyngeal lymph node involvement in HPV-associated oropharyngeal carcinoma: Patterns of involvement and impact on patient outcomesPatterns of Local-Regional Failure After Intensity Modulated Radiation Therapy or Passive Scattering Proton Therapy With Concurrent Chemotherapy for Non-Small Cell Lung Cancer
P50
Q26798037-FF89CABC-85A5-4C78-9945-FE9CB9781B1FQ26801289-90DA1DB3-D713-4DBF-B74D-F568B768FD98Q30249619-90B6EB35-6003-49A6-B4B0-289F3B36A36AQ31014100-1ADA5862-121A-49D1-B25E-216FD61F5DDBQ33426343-5B043F54-69A0-4434-8BE7-F0AD1B55E6C5Q35757310-A713A0E2-1BF5-40F3-9FDA-C36F6B5E98F7Q36003665-BD41048B-637D-44C8-B0A2-FCB3337F0614Q38253136-3BAAFCC3-6030-4BF1-95A5-D8FBB71E74F5Q38566770-656C1EC6-F8B0-45BC-BFCC-C135B5D9AB0DQ38586046-BAA1EBB5-B5DF-40DE-9135-70D14273C23CQ38591135-52470EDA-3E82-4E9E-A2E3-CE83E470010DQ38619215-93B6B6D5-0703-4585-BECD-1F50F9B40ED3Q38631710-4D34433E-092D-4E6E-BBBC-7DCA757C914BQ38699309-3E039929-D937-4041-8E36-8AEF18A5E9EBQ38720596-5967D4ED-3072-41D0-BD58-68B25AC83A73Q39025910-8768B151-860F-4352-AF58-35544321C4FDQ39131703-11200614-A9C1-4C3F-A21D-891E0279EC32Q40333279-70C1D842-EAB8-4DC9-9516-80E0DFA6D030Q41331956-A869B70B-B8D9-4E81-8087-719AAAF22837Q48156632-A91C9249-B41D-4244-B544-A4F130A67C5FQ52646249-875BAF7F-CDFA-4563-B036-AB1B6DA40127Q54940288-44B2A112-4C52-4A81-891A-5A6A1295745CQ56896384-2A41993E-0768-4E24-BBE0-4BBCBF086DFEQ57211742-0FCEA9C3-746D-4B5F-9EDC-83B6EDCC3339Q58130112-6B19AF81-0DC4-4B19-9C88-359C6496F5B8Q58601158-DDC1C888-3880-4251-A1E3-198E4819F57AQ58769400-797D6A8F-3CD5-44F7-AC8F-977B63F1F0FBQ58806059-69FD27FF-F57A-4CD5-AC1C-68C00B75FEE8Q60050043-D36FD129-DAF9-4E73-AD3B-2101C105E722Q61454646-94A02AC5-1C67-413E-8140-9AF3A5A02CEDQ61801038-C632FC78-0E51-4D22-841E-65BA52033765Q61805035-248F8DA5-E162-43F4-B1A0-7C2176AB70F3Q63365686-3C9D5545-276C-4F07-83A6-E619E292E64FQ87159028-279A83CE-BC63-48FD-ACC8-31C09A3F2D90Q89818741-219C8AB7-798E-4582-A591-F8FBA34904D8Q89983382-98D5777B-86C3-4BBD-AF9C-552024BB55FAQ90178665-102F87FA-E7F7-4A58-89D9-4437A65057E5Q90245726-728B5438-6F6B-49A3-AE67-08F8155E716BQ90941476-9C664B8A-4161-43CC-8E48-498F2692D675Q91232233-4F69C1C1-5C0D-4D72-BABE-3F494AC74182
P50
description
researcher ORCID ID = 0000-0001-9848-2623
@en
name
Hesham ElHalawani
@ast
Hesham ElHalawani
@en
Hesham ElHalawani
@es
Hesham ElHalawani
@nl
type
label
Hesham ElHalawani
@ast
Hesham ElHalawani
@en
Hesham ElHalawani
@es
Hesham ElHalawani
@nl
prefLabel
Hesham ElHalawani
@ast
Hesham ElHalawani
@en
Hesham ElHalawani
@es
Hesham ElHalawani
@nl
P108
P1153
56437730600
P31
P496
0000-0001-9848-2623